Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg for idiopathic small fiber neuropathy
NL-OMON47574Phase 3Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cryptogenic small fiber neuropathy (iSFN) comparing IVIg with Placebo (2 arms). Primary endpoint: Responder rate for pain improvement. Started Jul 2016; status: active, not recruiting.
02
Drugs
immune globulin
03
Conditions
cryptogenic small fiber neuropathy (iSFN)
Beyond the preview
Go deeper on NL-OMON47574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47574.